Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype.
Fetal growth restriction (FGR) is defined as the inability of a fetus to achieve its genetic growth potential and is associated with a significantly increased risk of morbidity and mortality. Clinically, FGR is diagnosed as a fetus falling below the 5(th) centile of customised growth charts. Sildena...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0077748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161893573918720 |
|---|---|
| author | Mark Robert Dilworth Irene Andersson Lewis James Renshall Elizabeth Cowley Philip Baker Susan Greenwood Colin Peter Sibley Mark Wareing |
| author_facet | Mark Robert Dilworth Irene Andersson Lewis James Renshall Elizabeth Cowley Philip Baker Susan Greenwood Colin Peter Sibley Mark Wareing |
| author_sort | Mark Robert Dilworth |
| collection | DOAJ |
| description | Fetal growth restriction (FGR) is defined as the inability of a fetus to achieve its genetic growth potential and is associated with a significantly increased risk of morbidity and mortality. Clinically, FGR is diagnosed as a fetus falling below the 5(th) centile of customised growth charts. Sildenafil citrate (SC, Viagra™), a potent and selective phosphodiesterase-5 inhibitor, corrects ex vivo placental vascular dysfunction in FGR, demonstrating potential as a therapy for this condition. However, many FGR cases present without an abnormal vascular phenotype, as assessed by Doppler measures of uterine/umbilical artery blood flow velocity. Thus, we hypothesized that SC would not increase fetal growth in a mouse model of FGR, the placental-specific Igf2 knockout mouse, which has altered placental exchange capacity but normal placental blood flow. Fetal weights were increased (by 8%) in P0 mice following maternal SC treatment (0.4 mg/ml) via drinking water. There was also a trend towards increased placental weight in treated P0 mice (P = 0.056). Additionally, 75% of the P0 fetal weights were below the 5(th) centile, the criterion used to define human FGR, of the non-treated WT fetal weights; this was reduced to 51% when dams were treated with SC. Umbilical artery and vein blood flow velocity measures confirmed the lack of an abnormal vascular phenotype in the P0 mouse; and were unaffected by SC treatment. (14)C-methylaminoisobutyric acid transfer (measured to assess effects on placental nutrient transporter activity) per g placenta was unaffected by SC, versus untreated, though total transfer was increased, commensurate with the trend towards larger placentas in this group. These data suggest that SC may improve fetal growth even in the absence of an abnormal placental blood flow, potentially affording use in multiple sub-populations of individuals presenting with FGR. |
| format | Article |
| id | doaj-art-eb030fce221e4da6a22d92be65c4be50 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-eb030fce221e4da6a22d92be65c4be502025-08-20T02:22:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7774810.1371/journal.pone.0077748Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype.Mark Robert DilworthIrene AnderssonLewis James RenshallElizabeth CowleyPhilip BakerSusan GreenwoodColin Peter SibleyMark WareingFetal growth restriction (FGR) is defined as the inability of a fetus to achieve its genetic growth potential and is associated with a significantly increased risk of morbidity and mortality. Clinically, FGR is diagnosed as a fetus falling below the 5(th) centile of customised growth charts. Sildenafil citrate (SC, Viagra™), a potent and selective phosphodiesterase-5 inhibitor, corrects ex vivo placental vascular dysfunction in FGR, demonstrating potential as a therapy for this condition. However, many FGR cases present without an abnormal vascular phenotype, as assessed by Doppler measures of uterine/umbilical artery blood flow velocity. Thus, we hypothesized that SC would not increase fetal growth in a mouse model of FGR, the placental-specific Igf2 knockout mouse, which has altered placental exchange capacity but normal placental blood flow. Fetal weights were increased (by 8%) in P0 mice following maternal SC treatment (0.4 mg/ml) via drinking water. There was also a trend towards increased placental weight in treated P0 mice (P = 0.056). Additionally, 75% of the P0 fetal weights were below the 5(th) centile, the criterion used to define human FGR, of the non-treated WT fetal weights; this was reduced to 51% when dams were treated with SC. Umbilical artery and vein blood flow velocity measures confirmed the lack of an abnormal vascular phenotype in the P0 mouse; and were unaffected by SC treatment. (14)C-methylaminoisobutyric acid transfer (measured to assess effects on placental nutrient transporter activity) per g placenta was unaffected by SC, versus untreated, though total transfer was increased, commensurate with the trend towards larger placentas in this group. These data suggest that SC may improve fetal growth even in the absence of an abnormal placental blood flow, potentially affording use in multiple sub-populations of individuals presenting with FGR.https://doi.org/10.1371/journal.pone.0077748 |
| spellingShingle | Mark Robert Dilworth Irene Andersson Lewis James Renshall Elizabeth Cowley Philip Baker Susan Greenwood Colin Peter Sibley Mark Wareing Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. PLoS ONE |
| title | Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. |
| title_full | Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. |
| title_fullStr | Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. |
| title_full_unstemmed | Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. |
| title_short | Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. |
| title_sort | sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype |
| url | https://doi.org/10.1371/journal.pone.0077748 |
| work_keys_str_mv | AT markrobertdilworth sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT ireneandersson sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT lewisjamesrenshall sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT elizabethcowley sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT philipbaker sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT susangreenwood sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT colinpetersibley sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype AT markwareing sildenafilcitrateincreasesfetalweightinamousemodeloffetalgrowthrestrictionwithanormalvascularphenotype |